VOHÁŇKA, Stanislav and Magda HORÁKOVÁ. Myastenie a anestezie (Myasthenia gravis and anesthesia). Neurologie pro praxi. Olomouc: Solen, 2017, vol. 18, No 5, p. 306-308. ISSN 1213-1814.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Myastenie a anestezie
Name (in English) Myasthenia gravis and anesthesia
Authors VOHÁŇKA, Stanislav (203 Czech Republic, belonging to the institution) and Magda HORÁKOVÁ (203 Czech Republic, guarantor, belonging to the institution).
Edition Neurologie pro praxi, Olomouc, Solen, 2017, 1213-1814.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30210 Clinical neurology
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/17:00098643
Organization unit Faculty of Medicine
Keywords (in Czech) nervosvalová ploténka; myastenie; myorelaxancia; inhibitory cholinesterázy; anestezie
Keywords in English neuromuscular junction; myasthenia gravis; neuromuscular blocking agents; cholinesterase inhibitors
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 19/3/2018 17:51.
Abstract
Myastenie je autoimunitní onemocnění nervosvalového přenosu. Řada léků používaných v anestezii s touto chorobou významně interferuje. Patří mezi ně především periferní myorelaxancia a volatilní plyny. Nemocníš myastenií mají změněnou citlivost především k periferním myorelaxanciím. Pokud je to možné, tak preferujeme regionální metody anestezie nebo jejich kombinaci. V pooperační péči je nutná pečlivá monitorace až do úplného zotavení pacienta. U myastenie nehrozí při použití jakýchkoliv anestetik maligní hypertermie.
Abstract (in English)
Myasthenia gravis is an autoimmune disorder of neuromuscular transmission. There are many drugs frequently used in anesthe-siology which interfere significantly with this disease. The most important are peripheral blocking agents and potent inhaled anesthetic agents. Patients suffering from myasthenia reveal modified sensitivity to these drugs, esp. to the peripheral blocking agents. Regional methods of the anesthesia or combination of both are preferred. Postoperative management is based on the careful monitoration of patients until full recovery is reached. In patient with myasthenia gravis there is no risk of malignant hyperthermia.
PrintDisplayed: 14/5/2024 22:34